Insulin lispro: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
Baris 99:
==Sejarah==
Insulin lispro (merek dagang Humalog) diberikan otorisasi pemasaran di Uni Eropa pada bulan April 1996,<ref name="Humalog EPAR">{{cite web | title=Humalog EPAR | website=[[European Medicines Agency]] (EMA) | date=11 February 2020 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/humalog | access-date=23 February 2020 | archive-date=24 February 2020 | archive-url=https://web.archive.org/web/20200224062204/https://www.ema.europa.eu/en/medicines/human/EPAR/humalog | url-status=live }}</ref> dan disetujui untuk digunakan di Amerika Serikat pada bulan Juni 1996.<ref name="FDA Humalog approval" /><ref>{{cite web | title=Humalog: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020563 | access-date=23 February 2020 | archive-date=27 November 2020 | archive-url=https://web.archive.org/web/20201127062846/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020563 | url-status=live }}</ref>
Insulin lispro (merek dagang Liprolog) diberikan otorisasi pemasaran di Uni Eropa pada bulan Mei 1997,<ref name="Liprolog EPAR">{{cite web | title=Liprolog EPAR | website=[[European Medicines Agency]] (EMA) | date=1 August 2001 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/liprolog | access-date=23 February 2020 | archive-date=24 February 2020 | archive-url=https://web.archive.org/web/20200224062116/https://www.ema.europa.eu/en/medicines/human/EPAR/liprolog | url-status=live }}</ref> dan pada bulan Agustus 2001.<ref>{{cite web | title=Liprolog EPAR | website=[[European Medicines Agency]] (EMA) | date=11 February 2020 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/liprolog-0 | access-date=23 February 2020 | archive-date=24 February 2020 | archive-url=https://web.archive.org/web/20200224062115/https://www.ema.europa.eu/en/medicines/human/EPAR/liprolog-0 | url-status=live }}</ref>
Obat kombinasi yang menggabungkan insulin lispro dan bentuk insulin lainnya disetujui untuk digunakan di Amerika Serikat pada bulan Desember 1999.<ref>{{cite web | title=Drug Approval Package: Humalog Mix (75/25 & 50/50) NDA# 21-017 & 21-018 | website=U.S. [[Food and Drug Administration]] (FDA) | date=24 December 1999 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21017_Humalog.cfm | access-date=23 February 2020 | archive-date=24 February 2020 | archive-url=https://web.archive.org/web/20200224062119/https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21017_Humalog.cfm | url-status=live }}</ref><ref>{{cite web | title=Humalog Mix50/50- insulin lispro injection, suspension Humalog Mix50/50 Kwikpen- insulin lispro injection, suspension | website=DailyMed | date=19 November 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b34cd3ff-d0af-4852-b4ef-2a8b4a93aeae | access-date=23 February 2020 | archive-date=28 August 2021 | archive-url=https://web.archive.org/web/20210828125609/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b34cd3ff-d0af-4852-b4ef-2a8b4a93aeae | url-status=live }}</ref><ref>{{cite web | title=Humalog Mix75/25- insulin lispro injection, suspension Humalog Mix75/25 Kwikpen- insulin lispro injection, suspension | website=DailyMed | date=3 February 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c73da51a-1899-45ad-b6cf-9c52c36a25dd | access-date=23 February 2020 | archive-date=30 November 2020 | archive-url=https://web.archive.org/web/20201130115850/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c73da51a-1899-45ad-b6cf-9c52c36a25dd | url-status=live }}</ref>
Insulin lispro Sanofi diberikan otorisasi pemasaran sebagai biosimilar di Uni Eropa pada bulan Juli 2017.<ref>{{cite web | title=Insulin lispro Sanofi EPAR | website=[[European Medicines Agency]] (EMA) | date=17 June 2019 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/insulin-lispro-sanofi | access-date=23 February 2020 | archive-date=24 February 2020 | archive-url=https://web.archive.org/web/20200224062115/https://www.ema.europa.eu/en/medicines/human/EPAR/insulin-lispro-sanofi | url-status=live }}</ref>
Insulin lispro injeksi (merek dagang Admelog) disetujui untuk digunakan di Amerika Serikat pada bulan Desember 2017.<ref>{{cite web | title=Drug Approval Package: Admelog (insulin lispro) | website=U.S. [[Food and Drug Administration]] (FDA) | date=17 May 2018 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209196Orig1s000TOC.cfm | access-date=23 February 2020 | archive-date=24 February 2020 | archive-url=https://web.archive.org/web/20200224062134/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209196Orig1s000TOC.cfm | url-status=live }}</ref><ref>{{cite press release | title=FDA Approves Sanofi's Admelog (insulin lispro injection) | website=Sanofi | date=11 December 2017 | url=http://www.news.sanofi.us/2017-12-11-FDA-Approves-Sanofis-Admelog-R-insulin-lispro-injection | access-date=23 February 2020 | archive-date=24 February 2020 | archive-url=https://web.archive.org/web/20200224055144/http://www.news.sanofi.us/2017-12-11-FDA-Approves-Sanofis-Admelog-R-insulin-lispro-injection | url-status=live }}</ref><ref>{{cite press release|title=FDA approves Admelog, the first short-acting "follow-on" insulin product to treat diabetes|url=https://www.fda.gov/news-events/press-announcements/fda-approves-admelog-first-short-acting-follow-insulin-product-treat-diabetes|website=U.S. [[Food and Drug Administration]] (FDA)|date=11 December 2017|access-date=12 December 2017|archive-date=14 June 2019|archive-url=https://web.archive.org/web/20190614022648/https://www.fda.gov/news-events/press-announcements/fda-approves-admelog-first-short-acting-follow-insulin-product-treat-diabetes|url-status=live}}</ref>
Pada bulan Januari 2020, Komite Produk Obat untuk Penggunaan Manusia (CHMP) dari [[Badan Pengawas Obat Eropa]] merekomendasikan pemberian otorisasi pemasaran untuk asam insulin lispro (nama merek Lyumjev) untuk pengobatan diabetes pada orang dewasa.<ref>{{cite web|date=30 January 2020|title=Lyumjev: Pending EC decision|url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/liumjev|access-date=23 February 2020|website=[[European Medicines Agency]] (EMA)|archive-date=31 January 2020|archive-url=https://web.archive.org/web/20200131193510/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/liumjev|url-status=dead}}</ref><ref>{{cite press release | title=CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes | website=Eli Lilly and Company | date=31 January 2020 | url=https://investor.lilly.com/news-releases/news-release-details/chmp-recommends-approval-lillys-new-fast-acting-mealtime-insulin | access-date=23 February 2020 | archive-date=28 August 2021 | archive-url=https://web.archive.org/web/20210828125611/https://investor.lilly.com/news-releases/news-release-details/chmp-recommends-approval-lillys-new-fast-acting-mealtime-insulin | url-status=live }}</ref> Insulin lispro (Lyumjev) disetujui untuk digunakan di [[Uni Eropa]] pada bulan Maret 2020, dan di Amerika Serikat pada bulan Juni 2020.<ref name="Liumjev EPAR">{{cite web|date=29 January 2020|title=Ljumjev EPAR|url=https://www.ema.europa.eu/en/medicines/human/EPAR/liumjev|access-date=16 April 2020|website=[[European Medicines Agency]] (EMA)|archive-date=28 August 2021|archive-url=https://web.archive.org/web/20210828125610/https://www.ema.europa.eu/en/medicines/human/EPAR/lyumjev-previously-liumjev|url-status=live}}</ref>
==Kegunaan dalam medis==
==Efek samping==
| |||